Oragenics Stock Price, News & Analysis

Oragenics, Inc. (NYSE American: OGEN) has provided a corporate update on its progress in developing ONP-002, a first-in-class neurosteroid for treating moderate to severe concussions. Key milestones in 2024 include:

1. Appointment of renowned experts as Chief Medical Officer and Chief Clinical Officer
2. Preparation for Phase II clinical trials
3. Successful completion of cardiotoxicity and genotoxicity tests
4. Partnership with Avance Clinical for trial execution
5. Achievement of temperature stability for ONP-002
6. Completion of spray-dry formulation and intranasal delivery devices
7. Development of a novel nanoparticle formulation increasing drug percentage by 4-fold
8. Successful intranasal casting studies for FDA approval

Oragenics raised over $6 million in 2024 to support ONP-002 development. The company plans to initiate Phase II trials later this year, starting in Australia followed by the U.S., to evaluate safety and efficacy in concussion patients.

Oragenics Inc. (NYSE American: OGEN) has successfully completed a key FDA-recognized study for its concussion drug, ONP-002. The study demonstrated that the intranasal delivery of ONP-002 effectively targets areas in the nose connected to the brain, increasing the likelihood of rapid brain treatment post-concussion. This achievement paves the way for Oragenics to proceed with Phase II human testing in emergency room patients, aiming to administer the first dose within 8 hours of injury.

The study utilized a special nasal spray device and an FDA-accepted anatomical model of the interior nose. Results showed promising drug distribution in areas where it can be quickly absorbed into the brain. With approximately 69 million people affected by concussions annually and no current pharmaceutical treatment available, ONP-002 represents a significant potential breakthrough in concussion treatment.

Oragenics, Inc. (NYSE American: OGEN), a company developing intranasal pharmaceuticals for neurological disorders, has closed its public offering of 3,078,378 common stock shares and 5,028,206 pre-funded warrants. The offering price was $0.55 per share and $0.549 per pre-funded warrant, with a $0.001 exercise price for each warrant. The company raised approximately $4.45 million in gross proceeds before deducting fees and expenses. Oragenics plans to use the funds for the continued development of its ONP-002 product candidate and general corporate purposes. Post-offering, Oragenics has 8,659,071 outstanding common stock shares and 5,028,206 outstanding pre-funded warrants. Dawson James Securities, Inc. acted as the sole placement agent for this offering.

Oragenics, Inc. (NYSE American: OGEN), a company developing intranasal pharmaceuticals for neurological disorders, has announced the pricing of a public offering. The company plans to sell 8,106,584 shares of common stock (or pre-funded warrants) at $0.55 per share. The offering is expected to close around September 5, 2024, with anticipated gross proceeds of $4.45 million. Oragenics intends to use the net proceeds to fund the development of its ONP-002 product candidate and for general corporate purposes. Dawson James Securities, Inc. is acting as the sole placement agent for this offering, which is being made pursuant to an effective registration statement filed with the SEC.

Oragenics Inc. (NYSE American: OGEN) has completed the spray-dried formulation and nasal device filling for its lead candidate, ONP-002, in preparation for a Phase IIa clinical trial targeting concussion treatment. The trial, set to enroll 40 concussed patients in Australia, will evaluate the efficacy of ONP-002 administered intranasally within 8 hours of injury. This novel neurosteroid aims to reduce negative outcomes post-concussion through its anti-inflammatory effects.

Key developments include:

• Production of placebo and ONP-002 as spray-dried nanoparticle formulations
• Loading of the powder into Oragenics' proprietary breath-propelled intranasal device
• Initiation of a stability program for both the drug formula and device

The trial design involves twice-daily dosing for five consecutive days, with patient-reported outcomes and blood biomarkers expected to be part of the evaluation process.

Oragenics (NYSE American: OGEN) has provided an update on its drug ONP-002, intended to treat concussion, and its non-compliance with NYSE American continued listing standards. Key developments include:

1. Demonstrated stability of ONP-002 across a wide temperature range.
2. Preparation for Phase 2 clinical trials, expected to start in Q4 2024.
3. Improved drug formulation, increasing ONP-002 per dose by 4X.
4. Developed prototype for automated intranasal device.
5. Completed FDA-required cardiotoxicity and genotoxicity testing.
6. Raised $1.1 million through a public offering.
7. Appointed new medical advisors.

The company is currently not in compliance with NYSE American's continued listing standards but has an approved Plan of Compliance until October 18, 2025.

Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, demonstrates stability across a wide temperature range (-20°C to 104°C). This eliminates the need for cold storage, making it suitable for field use in sports and military operations. Key points:

1. ONP-002 is a new chemical entity designed for intranasal delivery to treat concussions.
2. The drug maintains over 99% purity after 3 months at various temperatures.
3. Formulated as a spray-dried powder for improved stability.
4. No FDA-approved pharmaceutical treatment currently exists for concussions.
5. An estimated 69 million concussions are reported annually worldwide.

Oragenics aims to address the unmet medical need for concussion treatment, potentially impacting related neurological disorders like Alzheimer's, Parkinson's, and CTE.

Oragenics (NYSE American: OGEN) announced that its lead candidate for treating concussion, ONP-002, successfully completed an FDA-required genotoxicity study. The study showed that ONP-002 does not cause DNA damage or increase cancer risk in an animal model, even at high doses. This positive outcome clears a important safety hurdle for ONP-002, a new chemical entity designed for intranasal delivery to the brain.

Key points:

• ONP-002 showed no evidence of genetic mutations or cell cycle disruption
• The study was conducted under Good Laboratory (GLP) conditions
• Oragenics is planning a Phase II clinical trial for ONP-002
• Concussion affects an estimated 69 million people annually worldwide
• The company believes ONP-002 will be safe for concussed patients in the planned trial

Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, has successfully completed FDA-required cardiotoxicity testing. The drug showed no signs of causing cardiac arrhythmia, demonstrating a strong safety margin for the heart. This clearance allows Oragenics to proceed with planning Phase II clinical trials for concussion treatment.

ONP-002 is a new chemical entity designed for intranasal delivery to target the brain. The potential addressable market for ONP-002 is significant, with an estimated 69 million concussions reported annually worldwide. The total annual healthcare cost for nonfatal traumatic brain injuries in the US exceeds $40.6 billion, highlighting the substantial market opportunity for effective concussion treatments.